Trial Profile
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs JAB-3068 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jacobio Pharmaceuticals
- 25 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Jul 2021.
- 25 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jul 2021.
- 19 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Mar 2021.